-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Although diabetes and other abnormalities of glucose metabolism have been widely reported in the acute phase of COVID-19, less is known about the risk and burden of diabetes and associated outcomes in the late acute phase of COVID-19
181,280 In the post-acute phase of disease, patients with COVID-19 exhibited a higher risk of developing diabetes (HR 1.
In conclusion, the study shows that in the post-acute phase of the disease, patients with COVID-19 exhibit an increased risk and burden of diabetes and antihyperglycemic drug use
leave a message here
181,280 In the post-acute phase of disease, patients with COVID-19 exhibited a higher risk of developing diabetes (HR 1.
In conclusion, the study shows that in the post-acute phase of the disease, patients with COVID-19 exhibit an increased risk and burden of diabetes and antihyperglycemic drug use
Original source:
Yan Xie, et al.
leave a message here